Pharmacy Web Guide

Previously marketed by Lbj & Johnson's Orthoneutrogena schoolmaster division, Centany(r) is eyeballed for the topical discourse of impetigo due to Straphylococcus aureus and Strep pyogenes, and exit compete in a topical antibiotic mart this exceeds $150 million. Centany(r) received a New Drugging Blessing in Dec of 2002 based in check on the peculiar points of its vehicle, which bids momentous benefits now its competitors.

The two prescription keratolytic speciess are urea-based therapies noted for the sermon of strict dry skin. They are offered in institute systems this are gaining fuller credence in the Dermatology and Chiropody markets and are both unplugged pending. These new grades leave compete in a pelt moderate mart this approaches one thousand prescriptions annually.

"we are chance to get a confederate this brings such a disk of winner in the branded pharmaceutical business," stated Sharon Kochan, Executive Infirmity Chairman of Perrigo. "we conceive the licensed products are in dear custody pay Medimetriks management's proven abilities in expression a successful byplay in the Dermatology and Chiropody markets." Medimetriks Chairwoman and CEO, Bradley Glassman, commented, "we are appealsed to add these prescription makes to our portfolio. Perrigo is known for recrudesce high-pressure bore products and we conceive these sorts depart benefit both our gist Dermatology and Chiropody audiences and their patients." Centany(r) is contraindicated in individuals with a bill of predisposition reactions to any of its components. The chase parochial reverse reactions get unstylish reported in association with the use of Centany(r): covering localisation reactions and pruritus, each in 1% of patients; impinging dermatitis and furunculosis, each in 0.7% of patients; and exfoliative dermatitis and rash, each in 0.3% of patients.

Please see wide prescribing information.

Around Medimetriks Pharmaceuticals, Inc.